Table 1: Baseline characteristics of acute coronary syndrome patients receiving two different high-intensity atorvastatin doses (N= 626) Table 1: Baseline characteristics of acute coronary syndrome patients receiving two different high-intensity atorvastatin doses (N= 626) Table 1: Baseline characteristics of acute coronary syndrome patients receiving two different high-intensity atorvastatin doses (N= 626) Table 1: Baseline characteristics of acute coronary syndrome patients receiving two different high-intensity atorvastatin doses (N= 626) Table 1: Baseline characteristics of acute coronary syndrome patients receiving two different high-intensity atorvastatin doses (N= 626) Table 1: Baseline characteristics of acute coronary syndrome patients receiving two different high-intensity atorvastatin doses (N= 626) Table 1: Baseline characteristics of acute coronary syndrome patients receiving two different high-intensity atorvastatin doses (N= 626)
Characteristic
All Patients (N=626) n (%) All Patients (N=626) n (%) Atorvastatin 40mg Users (N=475) n (%) Atorvastatin 40mg Users (N=475) n (%) Atorvastatin 80mg Users (N=151) n (%)
P-value
Male gender 606 (96.8) 606 (96.8) 457 (96.2) 457 (96.2) 149 (98.7) 0.185*
Agea 50 ± 9.14 50 ± 9.14 50 ± 8.9 50 ± 8.9 48 ± 9.7 0.020
Weighta 77 ± 14.52 77 ± 14.52 77 ± 14.6 77 ± 14.6 77 ± 14.2 0.824
Region of origin 0.015*
Asia
455 (72.7)
455 (72.7)
358 (75.4)
358 (75.4)
97 (64.2)
Middle East
152 (24.3)
152 (24.3)
104 (21.9)
104 (21.9)
48 (31.8)
Africa
13 (2.1)
13 (2.1)
10 (2.1)
10 (2.1)
3 (2.0)
Europe
2 (0.3)
2 (0.3)
2 (0.4)
2 (0.4)
0
North America
3 (0.5)
3 (0.5)
1 (0.2)
1 (0.2)
2 (1.3)
South America
1 (0.2)
1 (0.2)
0
0
1 (0.7)
Smoking 293 (46.8) 293 (46.8) 214 (45.1) 214 (45.1) 79 (52.3) 0.376
Alcohol 46 (7.3) 46 (7.3) 27 (5.7) 27 (5.7) 19 (12.6) 0.005
Family history of CAD 97 (15.5) 97 (15.5) 67 (14.1) 67 (14.1) 30 (19.9) 0.091
Ejection fraction 1.0*
< 40%
102 (16.3)
102 (16.3)
77 (16.2)
77 (16.2)
25 (16.6)
> 40%
522 (83.4)
522 (83.4)
396 (83.4)
396 (83.4)
126 (83.4)
LDL-C (mg/dL) a 115 ± 43.4 115 ± 43.4 110 ± 41.9 110 ± 41.9 130 ± 44.7 <0.001
TC (mg/dL) a 185 ± 46.6 185 ± 46.6 181 ± 45.4 181 ± 45.4 196 ± 48.6 0.001
HDL (mg/dL) a 35 ± 9.9 35 ± 9.9 34 ± 9.9 34 ± 9.9 37 ± 9.7 0.010
HbA1c (%)a 7.2 ± 2.1 7.2 ± 2.1 7.2 ± 2.1 7.2 ± 2.1 7.3 ± 2.2 0.624
ALTa 33 ± 21.6 33 ± 21.6 34 ± 23.6 34 ± 23.6 30 ± 13.3 0.043
ASTa 40 ± 42.3 40 ± 42.3 43 ± 47.4 43 ± 47.4 30 ± 14.9 0.001
Hypertension Hypertension 254 (40.6) 198 (41.7) 56 (37.1) 56 (37.1) 0.316
Dyslipidemia Dyslipidemia 78 (12.5) 61 (12.8) 17 (11.3) 17 (11.3) 0.830*
Diabetes mellitus Diabetes mellitus 296 (47.3) 228 (48.0) 68 (45.0) 68 (45.0) 0.525
Chronic kidney disease Chronic kidney disease 15 (2.4) 12 (2.5) 3 (2.0) 3 (2.0) 1.0*
Hyperthyroidism Hyperthyroidism 1 (0.2) 1 (0.2) 0 0 1.0*
Hypothyroidism Hypothyroidism 10 (1.6) 8 (1.7) 2 (1.3) 2 (1.3) 1.0*
Peripheral artery disease Peripheral artery disease 2 (0.3) 2 (0.4) 0 0 1.0*
Coronary artery disease Coronary artery disease 73 (11.7) 64 (13.5) 9 (6.0) 9 (6.0) 0.012
Index event Index event
STEMI STEMI
377 (60.2)
261 (54.9)
116 (76.8)
116 (76.8)
<0.001
NSTEMI NSTEMI
210 (33.5)
180 (37.9)
30 (19.9)
30 (19.9)
<0.001
Unstable Angina Unstable Angina
35 (5.6)
30 (6.3)
5 (3.3)
5 (3.3)
0.162
PCI PCI 490 (78.3) 358 (75.4) 132 (87.4) 132 (87.4) 0.002
Primary PCI Primary PCI 252 (40.3) 186 (39.2) 66 (43.7) 66 (43.7) 0.501*
CABG CABG 17 (2.7) 17 (3.6) 0 0 0.023*
Drug eluting stent Drug eluting stent 411 (65.7) 299 (62.9) 112 (74.2) 112 (74.2) 0.035*
Bare metal stent Bare metal stent 83 (13.3) 68 (14.3) 15 (9.9) 15 (9.9) 0.292*
Coronary angiography access Coronary angiography access 0.347
Transradial Transradial
540 (86.3)
413 (86.9)
127 (84.1)
127 (84.1)
Transfemoral Transfemoral
75 (12)
54 (11.4)
21 (13.9)
21 (13.9)
Most common culprit lesions Most common culprit lesions
Proximal LAD Proximal LAD
227 (36.3)
179 (37.7)
48 (31.8)
48 (31.8)
0.142
Middle LAD Middle LAD
188 (30)
131 (27.6)
57 (37.7)
57 (37.7)
0.039
Proximal LCx Proximal LCx
98 (15.7)
80 (16.8)
18 (11.9)
18 (11.9)
0.134
Number of stents Number of stents 0.108
0 0
150 (24.0)
124 (26.1)
26 (17.2)
26 (17.2)
1 1
328 (52.4)
248 (52.2)
80 (53.0)
80 (53.0)
2 2
121 (19.3)
83 (17.5)
38 (25.2)
38 (25.2)
3 3
21 (3.3)
16 (3.4)
5 (3.3)
5 (3.3)
4 4
6 (1.0)
4 (0.8)
2 (1.3)
2 (1.3)
aValues are expressed as mean ± SD; *P-value was calculated using Fisher’s Exact test; CAD: coronary artery disease; LDL: low-density lipoproteins, TC: total cholesterol; HDL: high-density lipoproteins; HbA1c: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; LAD: left anterior descending artery; LCx: circumflex artery. aValues are expressed as mean ± SD; *P-value was calculated using Fisher’s Exact test; CAD: coronary artery disease; LDL: low-density lipoproteins, TC: total cholesterol; HDL: high-density lipoproteins; HbA1c: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; LAD: left anterior descending artery; LCx: circumflex artery. aValues are expressed as mean ± SD; *P-value was calculated using Fisher’s Exact test; CAD: coronary artery disease; LDL: low-density lipoproteins, TC: total cholesterol; HDL: high-density lipoproteins; HbA1c: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; LAD: left anterior descending artery; LCx: circumflex artery. aValues are expressed as mean ± SD; *P-value was calculated using Fisher’s Exact test; CAD: coronary artery disease; LDL: low-density lipoproteins, TC: total cholesterol; HDL: high-density lipoproteins; HbA1c: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; LAD: left anterior descending artery; LCx: circumflex artery. aValues are expressed as mean ± SD; *P-value was calculated using Fisher’s Exact test; CAD: coronary artery disease; LDL: low-density lipoproteins, TC: total cholesterol; HDL: high-density lipoproteins; HbA1c: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; LAD: left anterior descending artery; LCx: circumflex artery. aValues are expressed as mean ± SD; *P-value was calculated using Fisher’s Exact test; CAD: coronary artery disease; LDL: low-density lipoproteins, TC: total cholesterol; HDL: high-density lipoproteins; HbA1c: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; LAD: left anterior descending artery; LCx: circumflex artery. aValues are expressed as mean ± SD; *P-value was calculated using Fisher’s Exact test; CAD: coronary artery disease; LDL: low-density lipoproteins, TC: total cholesterol; HDL: high-density lipoproteins; HbA1c: glycated hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; LAD: left anterior descending artery; LCx: circumflex artery.